Question 1

What is the catalog number for JAK2, phosphorylated (Tyr931) discontinued?

Accepted Answer

The catalog number for JAK2, phosphorylated (Tyr931) discontinued is 538145.

Question 2

What sizes are available for JAK2, phosphorylated (Tyr931) discontinued?

Accepted Answer

JAK2, phosphorylated (Tyr931) discontinued is available in the following size(s): 30ul, 100 µL.

Question 3

How many pack sizes does JAK2, phosphorylated (Tyr931) discontinued come in?

Accepted Answer

JAK2, phosphorylated (Tyr931) discontinued is available in 2 different pack sizes.

Question 4

Is JAK2, phosphorylated (Tyr931) discontinued in stock?

Accepted Answer

JAK2, phosphorylated (Tyr931) discontinued is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

How do I reconstitute this lyophilized product?

Accepted Answer

Reconstitution instructions, including the recommended diluent and final concentration, are provided on the datasheet. Aliquot immediately after reconstitution to avoid repeated freeze-thaw cycles.

Question 6

What is the recommended incubation time for this antibody?

Accepted Answer

A suggested incubation time is provided in the recommended protocol on the datasheet, but may need adjusting depending on your sample type and detection system.

Question 7

What should I check when this product first arrives?

Accepted Answer

Inspect the package immediately for transportation damage, ice loss, leakage, or breakage. Report any issues right away with photos and your order reference; our specialists will determine whether the product is still usable or needs replacing.

JAK2, phosphorylated (Tyr931) discontinued

Product Specifications

Clonality

Available Sizes

Frequently Asked Questions

Explore Other Products

AMPK beta 1 (PRKAB1) Rabbit Polyclonal Antibody

Syntaxin 6 (STX6) (NM_005819) Human Over-expression Lysate

Human CDK5RAP1 activation kit by CRISPRa

Florfenicol Amine Hydrochloride

N-(Trifluoroacetyl)-L-tryptophan

Ceacam5 Mouse Gene Knockout Kit (CRISPR)